Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TSHA

Taysha Gene Therapies Inc

Feb 13 • 04:00PM ET

4.55

-0.10 -2.15 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT CRSP NTLA BLUE QURE EDIT IOVA ADVM SGMO GNFT

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA FESM KOMP

Index	RUT	P/E	-	EPS (ttm)	-0.35	Insider Own	20.14%	Shs Outstand	273.92M	Perf Week	-1.30%
Market Cap	1.25B	Forward P/E	-	EPS next Y	-0.43	Insider Trans	-2.27%	Shs Float	218.75M	Perf Month	-9.72%
Enterprise Value	1.02B	PEG	-	EPS next Q	-0.09	Inst Own	92.65%	Short Float	25.46%	Perf Quarter	4.36%
Income	-99.93M	P/S	197.52	EPS this Y	-0.40%	Inst Trans	2.18%	Short Ratio	18.16	Perf Half Y	54.76%
Sales	6.31M	P/B	5.69	EPS next Y	-18.96%	ROA	-40.23%	Short Interest	55.69M	Perf YTD	-17.27%
Book/sh	0.80	P/C	4.19	EPS next 5Y	-10.32%	ROE	-64.93%	52W High	6.02 -24.42%	Perf Year	180.86%
Cash/sh	1.09	P/FCF	-	EPS past 3/5Y	57.45% -63.99%	ROIC	-34.89%	52W Low	1.05 333.33%	Perf 3Y	325.23%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	81.77%	Volatility	5.95% 6.10%	Perf 5Y	-84.52%
Dividend TTM	-	EV/Sales	161.34	EPS Y/Y TTM	-945.72%	Oper. Margin	-1618.54%	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.47	Sales Y/Y TTM	-36.36%	Profit Margin	-1583.66%	RSI (14)	44.78	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	10.47	EPS Q/Q	2.83%	SMA20	-1.79%	Beta	0.99	Target Price	10.77
Payout	-	Debt/Eq	0.32	Sales Q/Q	-100.00%	SMA50	-10.34%	Rel Volume	0.68	Prev Close	4.65
Employees	73	LT Debt/Eq	0.31	Earnings	Nov 04 BMO	SMA200	22.71%	Avg Volume	3.07M	Price	4.55
IPO	Sep 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.01% -80.03%	Trades		Volume	2,094,350	Change	-2.15%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Raymond James	Strong Buy	$13
Jul-11-25	Initiated	BofA Securities	Buy	$8
Jun-27-24	Initiated	BMO Capital Markets	Outperform	$5
Apr-09-24	Initiated	Piper Sandler	Overweight	$9
Feb-01-23	Downgrade	Jefferies	Buy → Hold	$14 → $1.50
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$23 → $3
Nov-09-22	Downgrade	Goldman	Buy → Neutral	$16 → $3
Mar-09-22	Initiated	Robert W. Baird	Outperform	$26
Mar-01-22	Initiated	Wells Fargo	Overweight	$25
Feb-18-22	Initiated	SMBC Nikko	Outperform	$25
Dec-16-21	Initiated	Guggenheim	Buy	$28
Jul-16-21	Initiated	Needham	Buy	$45
Jun-24-21	Initiated	Truist	Buy	$60
Jun-15-21	Initiated	BTIG Research	Buy	$44
Jun-09-21	Initiated	Wedbush	Outperform	$31
Jun-08-21	Initiated	JMP Securities	Mkt Outperform	$40
May-19-21	Initiated	Cantor Fitzgerald	Overweight	$44
May-11-21	Resumed	Jefferies	Buy	$34 → $45
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform	$42

Show Previous Ratings

Feb-06-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 09:37AM	Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress (Insider Monkey)
Jan-29-26 01:48PM	Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) (Insider Monkey)
Jan-14-26 02:13PM	Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects (Insider Monkey)
Jan-06-26 08:00AM	Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome (GlobeNewswire) +7.57%
07:31AM	Loading…
Dec-21-25 07:31AM	Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program (Insider Monkey)
Dec-05-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.92%
Nov-18-25 06:17AM	Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? (Insider Monkey)
Nov-07-25 09:34PM	Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) (Insider Monkey)
Nov-04-25 04:09PM	Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -5.62%
07:00AM	Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-25 07:41AM	What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings (GuruFocus.com) -10.08%
Oct-28-25 08:00AM	Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 (GlobeNewswire)
Oct-26-25 06:16AM	Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum (Insider Monkey)
Oct-17-25 06:00AM	I-Mab morphs into hub-and-spoke biotech; Astellas passes on Taysha gene therapy (BioPharma Dive) -7.09%
03:14AM	Loading…
03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Oct-16-25 04:01PM	Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome (GlobeNewswire)
Oct-09-25 08:00AM	Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting (GlobeNewswire)
Oct-03-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Oct-02-25 08:00AM	Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome (GlobeNewswire) +53.46%
Sep-05-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 11:56PM	Piper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9 (Insider Monkey)
Aug-13-25 03:07AM	Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... (GuruFocus.com)
Aug-12-25 03:00PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.43%
08:01AM	Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:27AM	Earnings To Watch: Taysha Gene Therapies Inc (TSHA) Reports Q2 2025 Result (GuruFocus.com)
Aug-07-25 05:15PM	Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-05-25 04:05PM	Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-04-25 10:01AM	Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) (Insider Monkey)
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know (Zacks)
05:06PM	Loading…
Aug-01-25 05:06PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:47AM	BofA Securities Affirms 'Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects (Insider Monkey)
Jul-22-25 06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-16-25 12:00PM	Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jul-03-25 01:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 03:51PM	Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT (Insider Monkey)
Jun-18-25 09:16AM	Craig-Hallum bullish on Neurogene, initiates with a Buy (TipRanks)
Jun-06-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 05:17PM	Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program (GlobeNewswire)
May-29-25 12:12AM	Taysha Gene Therapies, Inc. (TSHA)'s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+ (Insider Monkey) +12.70%
May-28-25 10:40PM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.33%
04:02PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102 (GlobeNewswire)
May-16-25 03:19AM	Q1 2025 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents) +5.47%
03:09AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ... (GuruFocus.com)
May-15-25 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.02%
08:00AM	Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-25 09:40AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.53%
04:05PM	Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 (GlobeNewswire)
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -18.70% -5.00%
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
May-02-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha) +16.94%
Apr-15-25 04:04PM	Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity (Seeking Alpha) -7.09%
Apr-04-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.99%
Mar-19-25 04:31PM	Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? (InsiderMonkey) +5.17% -7.10%
Mar-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 01:04AM	Q4 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 09:15AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-25 10:57AM	Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-25 08:00AM	Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 (GlobeNewswire)
Feb-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.42%
Jan-03-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-24 12:51PM	Q3 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... (GuruFocus.com)
Nov-13-24 05:15PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.53%
04:01PM	Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-24 08:00AM	Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13 (GlobeNewswire) +7.87%
Nov-01-24 04:30PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.47% -12.42%
Oct-22-24 08:00AM	Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress (GlobeNewswire)
Oct-16-24 03:42PM	Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? (Insider Monkey)
Oct-14-24 12:00PM	Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why (Zacks)
Oct-04-24 08:01AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-24 04:55AM	Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5? (Insider Monkey)
Sep-26-24 08:00AM	Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress (GlobeNewswire)
Sep-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:01AM	Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-24 08:00AM	Taysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-02-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-26-24 09:14AM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -17.24%
08:36AM	Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today? (InvestorPlace)
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-25-24 06:34PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -7.33%
Jun-18-24 07:30AM	Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome (GlobeNewswire) -26.30%
07:02AM	Sanofi taps Belharra for immune drug research; AstraZenecas new cancer drug falls short (BioPharma Dive)
Jun-13-24 06:00AM	How to Invest in Penny Stocks in 2024: 3 Best Picks (InvestorPlace) +6.65%
Jun-12-24 07:00AM	Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire)
Jun-07-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 04:31PM	Is Taysha Gene Therapies, Inc. (NASDAQ:TSHA) the Best Gene Therapy Company? (Insider Monkey) +5.54%
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-15-24 03:11AM	Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com) +21.01%
May-14-24 08:57PM	TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +7.08%

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alam Kamran	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	4.52	1,655	7,481	1,442,131	Feb 06 04:30 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Feb 04 '26	Proposed Sale	4.72	901	4,253		Feb 04 06:44 PM
Fred Porter	Affiliate-Chief of Staff &	Feb 04 '26	Proposed Sale	4.72	889	4,196		Feb 04 06:42 PM
Sean McAuliffe	Affiliate - Chief Business Off	Feb 04 '26	Proposed Sale	4.72	914	4,314		Feb 04 06:41 PM
Rumana Haque-Ahmed	Officer	Feb 04 '26	Proposed Sale	4.72	697	3,290		Feb 04 06:39 PM
Kamran Alam	Officer	Feb 04 '26	Proposed Sale	4.72	1,655	7,812		Feb 04 06:38 PM
Nagendran Sukumar	President and Head of R&D	Jan 23 '26	Sale	4.75	89,132	423,377	1,344,307	Jan 27 04:05 PM
Nagendran Sukumar	President and Head of R&D	Jan 26 '26	Sale	4.61	26,918	124,092	1,317,389	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 23 '26	Sale	4.75	136,789	649,748	2,949,569	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 26 '26	Sale	4.61	41,312	190,448	2,908,257	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 23 '26	Sale	4.75	78,968	375,098	1,467,635	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	4.61	23,849	109,944	1,443,786	Jan 27 04:05 PM
Sean P. Nolan	Officer	Jan 23 '26	Proposed Sale	5.09	168,078	855,517		Jan 23 08:07 PM
Sukumar Nagendran	Officer	Jan 23 '26	Proposed Sale	5.09	113,824	579,364		Jan 23 08:05 PM
Rumana Haque-Ahmed	Officer	Jan 23 '26	Proposed Sale	5.09	30,052	152,965		Jan 23 08:04 PM
Fred Porter	Affiliate-Chief of Staff &	Jan 23 '26	Proposed Sale	5.09	54,916	279,522		Jan 23 08:02 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Jan 23 '26	Proposed Sale	5.09	32,077	163,272		Jan 23 08:01 PM
Sean McAuliffe	Affiliate - Chief Business Off	Jan 23 '26	Proposed Sale	5.09	46,064	234,466		Jan 23 07:59 PM
Kamran Alam	Officer	Jan 23 '26	Proposed Sale	5.09	100,846	513,306		Jan 23 07:58 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Option Exercise	1.15	200,000	229,440	1,206,439	Jan 14 04:45 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Sale	4.71	200,000	942,000	1,006,439	Jan 14 04:45 PM
Nagendran Sukumar	Officer	Jan 12 '26	Proposed Sale	4.98	200,000	996,000		Jan 12 04:19 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Option Exercise	1.71	260,047	444,680	1,266,486	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Option Exercise	1.07	110,125	117,363	1,116,564	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Sale	4.51	260,047	1,172,812	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Sale	4.75	110,125	523,094	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	Officer	Nov 28 '25	Proposed Sale	4.86	370,172	1,799,036		Nov 28 01:07 PM
Rumana Haque-Ahmed	Officer	Sep 22 '25	Proposed Sale	2.83	10,770	30,479		Sep 22 07:18 PM
Nagendran Sukumar	President and Head of R&D	Sep 10 '25	Option Exercise	0.70	41,150	28,760	1,206,439	Sep 12 04:15 PM
Nagendran Sukumar	President and Head of R&D	Sep 10 '25	Sale	3.23	200,000	646,000	1,006,439	Sep 12 04:15 PM
Nagendran Sukumar	Officer	Sep 10 '25	Proposed Sale	3.26	200,000	652,000		Sep 10 04:28 PM
Nagendran Sukumar	President and Head of R&D	Aug 21 '25	Sale	2.85	57,054	162,604	1,165,289	Aug 22 04:15 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Aug 21 '25	Sale	2.85	54,491	155,299	1,187,603	Aug 22 04:15 PM
Kamran Alam	Officer	Aug 21 '25	Proposed Sale	2.87	54,491	156,389		Aug 21 09:12 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Aug 21 '25	Proposed Sale	2.87	19,604	56,263		Aug 21 09:11 PM
Sukumar Nagendran	Officer	Aug 21 '25	Proposed Sale	2.87	57,054	163,745		Aug 21 09:10 PM
Sean McAuliffe	Affiliate - Chief Business Off	Aug 21 '25	Proposed Sale	2.87	27,590	79,183		Aug 21 09:09 PM
Fred Porter	Affiliate-Chief of Staff &	Aug 21 '25	Proposed Sale	2.87	50,451	144,794		Aug 21 09:08 PM
Manning Paul B	10% Owner	May 30 '25	Buy	2.75	750,000	2,062,500	2,841,704	Jun 03 09:38 PM

Open in Screener

CADL

Candel Therapeutics Inc

Feb 13 • 04:00PM ET

5.68

+0.08 1.43 %

Healthcare • Biotechnology • USA • NASD

CADL Candel Therapeutics Inc daily Stock Chart

Peers: ADAP IMTX XBIT ZNTL LONA MRNS PPBT BLRX CYPH ADIL

| Held by: VTI IWM VXF IWO IBB VTWO IWC SBIO VTWG IWN

Index	RUT	P/E	-	EPS (ttm)	-0.56	Insider Own	25.21%	Shs Outstand	54.90M	Perf Week	-2.57%
Market Cap	311.82M	Forward P/E	-	EPS next Y	-1.06	Insider Trans	0.00%	Shs Float	41.06M	Perf Month	-8.53%
Enterprise Value	232.07M	PEG	-	EPS next Q	-0.24	Inst Own	38.59%	Short Float	22.79%	Perf Quarter	15.45%
Income	-22.76M	P/S	-	EPS this Y	75.77%	Inst Trans	0.60%	Short Ratio	11.76	Perf Half Y	-5.96%
Sales	0.00M	P/B	3.89	EPS next Y	-150.46%	ROA	-39.54%	Short Interest	9.36M	Perf YTD	0.53%
Book/sh	1.46	P/C	3.59	EPS next 5Y	34.45%	ROE	-70.17%	52W High	13.68 -58.48%	Perf Year	-35.60%
Cash/sh	1.58	P/FCF	-	EPS past 3/5Y	-11.43% -43.86%	ROIC	-27.53%	52W Low	4.25 33.65%	Perf 3Y	179.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.13% 6.38%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	68.53%	Oper. Margin	-	ATR (14)	0.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.02	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	8.25	EPS Q/Q	38.27%	SMA20	-3.48%	Beta	-0.90	Target Price	18.62
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	-1.94%	Rel Volume	0.59	Prev Close	5.60
Employees	38	LT Debt/Eq	0.03	Earnings	Nov 13 BMO	SMA200	2.32%	Avg Volume	795.63K	Price	5.68
IPO	Jul 27, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.39% -	Trades		Volume	473,160	Change	1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-28-25	Initiated	Stephens	Overweight	$15
Sep-03-25	Downgrade	BofA Securities	Buy → Neutral	$7
Jun-30-25	Resumed	H.C. Wainwright	Buy	$23
Feb-20-25	Initiated	Citigroup	Buy	$25
Feb-19-25	Initiated	Canaccord Genuity	Buy	$20
Feb-07-25	Initiated	BofA Securities	Buy	$15
Dec-02-22	Initiated	H.C. Wainwright	Buy	$11
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$18
Aug-23-21	Initiated	UBS	Buy	$9
Aug-23-21	Initiated	Jefferies	Buy	$22
Aug-23-21	Initiated	Credit Suisse	Outperform	$15

Show Previous Ratings

Feb-11-26 08:05AM	Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit (GlobeNewswire)
Feb-02-26 04:05PM	Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-20-26 09:12AM	New Strong Sell Stocks for January 20th (Zacks) -7.50%
Nov-17-25 04:05PM	Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 (GlobeNewswire)
Nov-13-25 08:25AM	Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.30%
09:00AM	Loading…
Nov-04-25 09:00AM	Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors (GlobeNewswire)
Nov-03-25 08:05AM	Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-16-25 08:05AM	Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board (GlobeNewswire) -9.29%
Oct-15-25 08:31AM	Candel Therapeutics announces interim data from phase 1b CAN-3110 trial (TipRanks)
Oct-14-25 08:10AM	Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer (PR Newswire) -10.74%
08:10AM	Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. (GlobeNewswire)
08:05AM	Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine (GlobeNewswire)
Oct-03-25 09:05AM	Candel Therapeutics to Present at the SITC 2025 Annual Meeting (GlobeNewswire)
Sep-29-25 08:05AM	Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
Sep-17-25 08:05AM	Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
08:05AM	Loading…
Sep-02-25 08:05AM	Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board (GlobeNewswire)
Aug-28-25 08:05AM	Candel Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-14-25 08:05AM	Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.63%
Jul-30-25 08:05AM	Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-25-25 08:23AM	Candel Therapeutics' CAN-2409 gains EMA orphan designation (Pharmaceutical Business Review)
Jul-24-25 08:05AM	Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jul-09-25 08:05AM	Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution (GlobeNewswire) +16.22%
Jun-25-25 12:00PM	Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jun-24-25 09:05AM	Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock (GlobeNewswire)
Jun-23-25 08:05AM	Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer (GlobeNewswire)
Jun-06-25 08:05AM	Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire) +8.83%
Jun-02-25 09:55AM	Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? (Zacks)
May-29-25 11:41PM	Candel Therapeutics, Inc. (CADL)'s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer (Insider Monkey) -6.84%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
May-28-25 08:05AM	Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer (GlobeNewswire) +6.07%
08:05AM	Loading…
May-27-25 08:05AM	Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation (GlobeNewswire)
May-23-25 01:46AM	Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 (Insider Monkey)
May-22-25 05:05PM	Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire)
May-19-25 10:00AM	Best Momentum Stocks to Buy for May 19th (Zacks) +6.54%
07:49AM	New Strong Buy Stocks for May 19th (Zacks)
May-16-25 09:55AM	Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know (Zacks)
May-13-25 08:05AM	Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +7.68%
May-06-25 08:05AM	Candel Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -7.83%
Apr-23-25 04:05PM	Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire) +5.04%
Apr-01-25 08:01AM	Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients (GlobeNewswire)
Mar-27-25 03:46PM	Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients (Benzinga) -7.33%
Mar-26-25 04:05PM	Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment (GlobeNewswire) -8.76%
Mar-25-25 09:55AM	Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now (Zacks) -5.08%
Mar-20-25 08:00AM	Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 (GlobeNewswire) -7.30%
Mar-18-25 08:00AM	Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board (GlobeNewswire)
Mar-13-25 04:15PM	Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.20%
Feb-25-25 01:58PM	Candel Therapeutics stock drops despite OS improvement in PDAC trial (Clinical Trials Arena) -23.49%
08:00AM	Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Jan-13-25 08:00AM	Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 (GlobeNewswire) -5.01%
Jan-09-25 01:44AM	After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win (Pharma Voice)
Dec-19-24 01:44PM	Hedge Fund and Insider Trading News: Simon Sadler, Stanley Druckenmiller, Warren Buffett, Caxton Associates, Millennium Management, Saba Capital, Candel Therapeutics Inc (CADL), NVIDIA Corp (NVDA), and More (Insider Monkey) +52.53%
Dec-16-24 04:01PM	Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.81% +7.23%
Dec-12-24 11:00PM	Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire) +26.45% -31.12%
04:51PM	Candel Therapeutics Announces $80 Million Proposed Public Offering (GlobeNewswire)
Dec-11-24 04:09PM	Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily) +68.11%
01:07PM	Candel Therapeutics Prostate Cancer Therapy Shows Promise (Exec Edge)
11:54AM	Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily)
10:32AM	Candel Therapeutics stock up 172% after Phase III prostate cancer success (Clinical Trials Arena)
09:19AM	Candel Therapeutics Stock Surges Over 100% - Here's Why (Benzinga)
07:00AM	Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival (GlobeNewswire)
Nov-14-24 08:00AM	Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-07-24 08:00AM	Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 (GlobeNewswire)
Nov-05-24 09:00AM	Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma (GlobeNewswire)
Oct-29-24 08:59AM	Candel Therapeutics Advances in Cancer Treatment Trials (TipRanks)
Oct-28-24 08:00AM	Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) (GlobeNewswire)
Oct-04-24 09:00AM	Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting (GlobeNewswire)
Sep-04-24 08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire)
Sep-03-24 08:00AM	Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.52%
Aug-13-24 08:00AM	Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Jun-18-24 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -6.93%
Jun-14-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments (News Direct)
07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-11-24 08:00AM	Candel Therapeutics to Join Russell 3000 Index (GlobeNewswire) +7.40%
Jun-07-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers (News Direct)
Jun-03-24 08:30AM	Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer (News Direct) -5.96%
May-30-24 08:00AM	FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma (GlobeNewswire)
May-28-24 11:07AM	Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why (Zacks) +9.62%
May-24-24 11:42AM	Candel (CADL) Reports Upbeat Data From Lung Cancer Study (Zacks) -27.03%
May-23-24 05:00PM	Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting (GlobeNewswire)
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-22-24 08:00AM	Candel Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -13.77%
May-20-24 08:00AM	Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire) +30.84%
May-14-24 01:53PM	CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -7.94%
Apr-25-24 08:00AM	Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire) +6.28%
Apr-12-24 10:00AM	Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag (Zacks) -8.52%
Apr-11-24 09:00AM	Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire) +42.75%
Apr-09-24 08:00AM	Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors (GlobeNewswire) -20.84%
Apr-05-24 12:10PM	Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study (Zacks)
Apr-04-24 12:24PM	After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study (Benzinga) +280.95%
08:00AM	Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Mar-28-24 04:05PM	Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma (GlobeNewswire) +10.76%
01:53PM	CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
08:05AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-15-24 08:15AM	Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors (News Direct)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Option Exercise	1.29	937	1,209	53,430	Jul 30 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Sale	6.98	937	6,540	52,493	Jul 30 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Option Exercise	1.29	781	1,007	53,274	Jul 02 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Sale	5.04	781	3,936	52,493	Jul 02 04:30 PM
WILLIAM GARRETT NICHOLS	Officer	Jun 30 '25	Proposed Sale	4.90	3,593	17,606		Jun 30 04:19 PM
Nichols William Garrett	Chief Medical Officer	Mar 18 '25	Option Exercise	1.90	18,489	35,127	97,809	Mar 20 04:36 PM
Nichols William Garrett	Chief Medical Officer	Mar 18 '25	Sale	8.76	45,316	396,995	52,493	Mar 20 04:36 PM
Barone Francesca	Chief Scientific Officer	Mar 18 '25	Option Exercise	1.55	18,000	27,900	128,673	Mar 20 04:36 PM
Barone Francesca	Chief Scientific Officer	Mar 18 '25	Sale	8.76	32,146	281,673	96,527	Mar 20 04:36 PM
Tak Paul Peter	Chief Executive Officer	Mar 18 '25	Sale	8.77	25,772	226,023	226,140	Mar 20 04:35 PM
Tak Paul Peter	Chief Executive Officer	Mar 19 '25	Sale	9.00	400	3,601	225,740	Mar 20 04:35 PM
Tyagarajan Seshu	Chief Technology Officer	Mar 17 '25	Sale	8.82	31,278	275,947	85,512	Mar 19 04:12 PM
Schoch Charles	See Remarks	Mar 17 '25	Sale	8.83	5,000	44,169	38,038	Mar 19 04:06 PM
FRANCESCA BARONE	Officer	Mar 18 '25	Proposed Sale	8.83	32,146	283,849		Mar 18 04:29 PM
PAUL PETER TAK	Director	Mar 18 '25	Proposed Sale	8.83	74,106	654,356		Mar 18 04:29 PM
WILLIAM GARRETT NICHOLS	Officer	Mar 18 '25	Proposed Sale	8.83	45,316	400,140		Mar 18 04:28 PM
SESHU TYAGARAJAN	Officer	Mar 17 '25	Proposed Sale	8.75	31,278	273,682		Mar 17 04:29 PM
CHARLES SCHOCH	Officer	Mar 17 '25	Proposed Sale	8.75	5,000	43,750		Mar 17 04:29 PM

Open in Screener

VRCA

Verrica Pharmaceuticals Inc

Feb 13 • 04:00PM ET

5.69

+0.13 2.34 %

Healthcare • Biotechnology • USA • NASD

VRCA Verrica Pharmaceuticals Inc daily Stock Chart

Peers: DERM HRTX ACRS SUPN CLSD KPTI XERS ADMA DMAC EYPT

| Held by: VXF VTI AVTM

Index	-	P/E	-	EPS (ttm)	-3.44	Insider Own	91.54%	Shs Outstand	9.49M	Perf Week	-17.66%
Market Cap	90.98M	Forward P/E	-	EPS next Y	-1.60	Insider Trans	40.73%	Shs Float	1.35M	Perf Month	-28.43%
Enterprise Value	105.62M	PEG	-	EPS next Q	-0.73	Inst Own	19.83%	Short Float	25.04%	Perf Quarter	48.95%
Income	-26.01M	P/S	2.95	EPS this Y	92.66%	Inst Trans	11.46%	Short Ratio	1.36	Perf Half Y	-7.48%
Sales	30.83M	P/B	-	EPS next Y	-47.70%	ROA	-70.48%	Short Interest	0.34M	Perf YTD	-31.53%
Book/sh	-1.80	P/C	4.31	EPS next 5Y	57.83%	ROE	-1546.58%	52W High	9.82 -42.06%	Perf Year	-12.72%
Cash/sh	1.32	P/FCF	-	EPS past 3/5Y	-4.45% -5.46%	ROIC	-469.74%	52W Low	3.28 73.48%	Perf 3Y	-92.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-14.25% -	Gross Margin	91.36%	Volatility	9.09% 7.01%	Perf 5Y	-95.83%
Dividend TTM	-	EV/Sales	3.43	EPS Y/Y TTM	81.16%	Oper. Margin	-51.14%	ATR (14)	0.53	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.11	Sales Y/Y TTM	234.73%	Profit Margin	-84.38%	RSI (14)	31.33	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.19	EPS Q/Q	99.41%	SMA20	-18.49%	Beta	1.48	Target Price	16.50
Payout	-	Debt/Eq	-	Sales Q/Q	905.39%	SMA50	-25.84%	Rel Volume	0.58	Prev Close	5.56
Employees	71	LT Debt/Eq	-	Earnings	Nov 14 AMC	SMA200	-4.97%	Avg Volume	247.86K	Price	5.69
IPO	Jun 15, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	92.06% 47.06%	Trades		Volume	144,855	Change	2.34%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

Feb-12-26 08:00AM	Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer (GlobeNewswire)
Feb-09-26 08:00AM	Verrica Pharmaceuticals Announces Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical (GlobeNewswire)
Feb-02-26 12:00PM	Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why (Zacks) +5.97%
05:59AM	New Strong Buy Stocks for February 2nd (Zacks)
Jan-12-26 09:55AM	How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% (Zacks)
08:00AM	Loading…
Jan-07-26 08:00AM	Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts (GlobeNewswire)
Nov-24-25 08:00AM	Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway (GlobeNewswire) +12.11%
Nov-17-25 04:00PM	Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com) -5.09%
Nov-14-25 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-10-25 08:00AM	Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +11.85%
Oct-24-25 11:00AM	Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 04:05PM	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union (GlobeNewswire) +7.95% -9.82%
Oct-07-25 04:05PM	Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-19-25 08:00AM	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum (GlobeNewswire) +8.66%
Sep-02-25 07:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
03:12AM	Loading…
Aug-13-25 03:12AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Aug-12-25 05:20PM	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 09:42AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.51%
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.20%
07:00AM	Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 (GlobeNewswire)
Jul-09-25 07:00AM	Verrica Pharmaceuticals Reports Strong Growth in YCANTH Dispensed Applicator Units in 2Q 2025 (GlobeNewswire)
Jul-01-25 07:00AM	Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire) +13.37%
May-28-25 08:00AM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire) -5.78%
May-14-25 08:10AM	Q1 2025 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ... (GuruFocus.com)
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.63%
04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +15.07%
09:52AM	Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result (GuruFocus.com)
05:50PM	Loading…
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.97%
May-07-25 08:00AM	Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 (GlobeNewswire) -9.20%
May-02-25 07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates (Zacks)
Apr-30-25 08:00AM	Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York (GlobeNewswire)
Apr-07-25 08:00AM	Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH Dispensed Applicator Units in First Quarter 2025 (GlobeNewswire) +21.75%
Apr-02-25 04:05PM	Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors (GlobeNewswire)
Apr-01-25 09:55AM	Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-31-25 08:00AM	Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-25 07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.75%
Mar-12-25 01:48PM	Q4 2024 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.56%
03:08AM	Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Mar-11-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 07:00AM	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 (GlobeNewswire)
Feb-27-25 10:00AM	Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -16.89%
Feb-25-25 04:05PM	Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston (GlobeNewswire)
Jan-21-25 07:00AM	Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference (GlobeNewswire) +5.12%
Dec-20-24 07:00AM	Verrica Provides Business and Operational Update (GlobeNewswire)
Dec-09-24 04:15PM	Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.94% -7.84%
Dec-06-24 08:00AM	Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-21-24 07:30AM	Verrica Announces Pricing of $42.0 Million Public Offering (GlobeNewswire) +11.56%
Nov-20-24 04:05PM	Verrica Announces Proposed Public Offering (GlobeNewswire)
Nov-04-24 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition (GlobeNewswire) -6.54% -44.23%
Oct-24-24 07:00AM	Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-09-24 06:21PM	Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
Oct-02-24 07:30AM	Verrica Pharmaceuticals Announces Restructuring of Commercial Organization (GlobeNewswire) -18.98%
Sep-29-24 08:02AM	Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:27AM	Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? (Insider Monkey) -5.68%
Sep-20-24 05:21AM	Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) (Newsfile) -6.70%
Sep-04-24 07:30AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York (GlobeNewswire) +5.50%
Aug-15-24 07:32AM	Verrica stock drops after half patients tumours gone in skin cancer trial (Clinical Trials Arena) -6.73%
Aug-14-24 09:52AM	Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -40.80%
08:55AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma (GlobeNewswire)
Aug-06-24 07:30AM	Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 (GlobeNewswire) -5.45%
Jul-15-24 11:57AM	7 Short-Squeeze Stocks That Could Beat Down the Bears (InvestorPlace)
Jul-01-24 07:30AM	Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. (GlobeNewswire) +9.05%
May-30-24 04:30PM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)
08:40AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Verrica Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-08-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-06-24 06:35AM	Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire) +5.00%
Feb-22-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 07:30AM	Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition (GlobeNewswire) -7.58%
Jan-29-24 07:30AM	Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services (GlobeNewswire)
Jan-22-24 07:44PM	7 Potential Short-Squeeze Stocks Poised for Rapid Gains (InvestorPlace)
Jan-05-24 07:30AM	Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jan-04-24 07:30AM	Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts (GlobeNewswire)
Jan-03-24 07:30AM	Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH (GlobeNewswire)
Dec-15-23 01:49PM	Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? (InvestorPlace) +61.97%
06:00AM	Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-11-23 10:13AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 08:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-09-23 07:30AM	Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire) -9.83%

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenberg Noah L.	CMO	Nov 25 '25	Buy	4.24	2,357	10,000	2,357	Nov 25 07:00 PM
Kirby John J.	Interim CFO	Nov 25 '25	Buy	4.24	3,536	15,001	8,962	Nov 25 07:00 PM
Zawitz David	Chief Operating Officer	Nov 25 '25	Buy	4.24	10,000	42,425	21,000	Nov 25 07:00 PM
Rieger Jayson	CEO and President	Nov 25 '25	Buy	4.24	94,311	400,114	182,593	Nov 25 07:00 PM
Manning Paul B	Director	Nov 25 '25	Buy	4.24	2,750,762	11,670,108	3,348,372	Nov 25 07:00 PM
Manning Paul B	Director	Nov 25 '25	Buy	4.24	1,375,380	5,835,050	3,958,189	Nov 25 07:00 PM
Hayes Christopher G.	CHIEF LEGAL OFFICER	Mar 17 '25	Sale	0.65	4,315	2,805	176,458	Mar 18 06:45 PM

Open in Screener

LQDA

Liquidia Corp

Feb 13 • 04:00PM ET

38.20

-0.84 -2.15 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY SRPT NBIX ARWR IONS RGEN MDGL XNCR

| Held by: VTI IWM VXF IWO PJP SCHA VTWO KOMP IHE XPH

Index	RUT	P/E	-	EPS (ttm)	-1.43	Insider Own	17.65%	Shs Outstand	86.82M	Perf Week	-11.25%
Market Cap	3.32B	Forward P/E	19.09	EPS next Y	2.00	Insider Trans	-7.69%	Shs Float	71.64M	Perf Month	-4.48%
Enterprise Value	3.36B	PEG	-	EPS next Q	0.19	Inst Own	68.59%	Short Float	17.84%	Perf Quarter	34.93%
Income	-121.85M	P/S	48.01	EPS this Y	56.79%	Inst Trans	0.19%	Short Ratio	7.34	Perf Half Y	46.42%
Sales	69.22M	P/B	150.39	EPS next Y	378.99%	ROA	-46.08%	Short Interest	12.78M	Perf YTD	10.76%
Book/sh	0.25	P/C	21.10	EPS next 5Y	-	ROE	-183.82%	52W High	46.67 -18.15%	Perf Year	136.68%
Cash/sh	1.81	P/FCF	-	EPS past 3/5Y	-33.51% 8.44%	ROIC	-73.96%	52W Low	11.26 239.25%	Perf 3Y	451.23%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-3.36% 11.64%	Gross Margin	87.62%	Volatility	5.96% 6.47%	Perf 5Y	1068.20%
Dividend TTM	-	EV/Sales	48.61	EPS Y/Y TTM	11.91%	Oper. Margin	-154.98%	ATR (14)	2.55	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.96	Sales Y/Y TTM	343.41%	Profit Margin	-176.04%	RSI (14)	44.91	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	2.20	EPS Q/Q	86.17%	SMA20	-8.08%	Beta	0.50	Target Price	45.67
Payout	-	Debt/Eq	9.03	Sales Q/Q	1121.72%	SMA50	2.47%	Rel Volume	0.60	Prev Close	39.04
Employees	157	LT Debt/Eq	6.47	Earnings	Nov 03 BMO	SMA200	51.72%	Avg Volume	1.74M	Price	38.20
IPO	Jul 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	89.73% 188.24%	Trades		Volume	1,048,554	Change	-2.15%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$31
Aug-15-25	Resumed	Jefferies	Buy	$43
May-19-25	Downgrade	Oppenheimer	Perform → Underperform	$13
Dec-20-24	Initiated	Wells Fargo	Overweight	$20
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform	$27
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

Feb-12-26 11:40AM	EXEL or LQDA: Which Is the Better Value Stock Right Now? (Zacks)
Jan-27-26 08:30AM	Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress (GlobeNewswire)
Jan-16-26 08:29AM	Laughing Water Capital's Updates on Liquidia Corp (LQDA) (Insider Monkey)
Jan-15-26 12:00PM	Liquidia Corporation (LQDA) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-09-26 07:09PM	Why Liquidia Stock Rocked the Market Today (Motley Fool) +12.91%
06:30AM	Loading…
06:30AM	Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update (GlobeNewswire)
Jan-08-26 11:40AM	HRMY vs. LQDA: Which Stock Is the Better Value Option? (Zacks)
Jan-07-26 07:00AM	Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-25 09:06AM	Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus (Zacks)
Dec-11-25 09:22AM	Arquitos Capital Management's Updates on Liquidia Corporation (LQDA) (Insider Monkey)
Nov-24-25 09:55AM	Wall Street Analysts See a 51.15% Upside in Liquidia Corporation (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
Nov-16-25 10:14PM	Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA's 75% Growth in U.S. Prostacyclin Revenue (Insider Monkey)
Nov-06-25 09:55AM	Wall Street Analysts Think Liquidia Corporation (LQDA) Could Surge 62.34%: Read This Before Placing a Bet (Zacks)
Nov-05-25 06:39AM	Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment (Insider Monkey) -5.34%
04:02PM	Loading…
Nov-03-25 04:02PM	Liquidia Corp (LQDA) Q3 2025 Earnings Call Highlights: Strong YUTREPIA Sales Drive Positive ... (GuruFocus.com) +10.67%
08:00AM	Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences (GlobeNewswire)
06:30AM	Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 09:21AM	Liquidia Corp (LQDA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
Oct-28-25 10:00AM	Niagen Bioscience (NAGE) Reports Next Week: What to Expect (Zacks)
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-27-25 08:30AM	Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-21-25 09:55AM	Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade (Zacks)
Oct-16-25 04:33PM	BofA Securities Raises Liquidia Corporation (LQDA) PT to $37, Reiterates Buy Rating (Insider Monkey)
Oct-07-25 06:30AM	Liquidia Corporation to Host R&D Day in New York City on October 28, 2025 (GlobeNewswire) +5.10%
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
Sep-29-25 08:30AM	Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting (GlobeNewswire)
Sep-24-25 04:06AM	Liquidia Corporation (LQDA) Presents Strategic Overview at Well Fargo's Annual Healthcare Conference 2025 (Insider Monkey)
10:32AM	Loading…
Sep-23-25 10:32AM	Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares? (Insider Monkey)
Sep-16-25 02:15PM	Liquidia Corporation (LQDA): A Bull Case Theory (Insider Monkey)
Sep-11-25 08:30AM	Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium (GlobeNewswire)
Sep-04-25 01:14PM	Jefferies Highlights Yutrepia's Market Edge in Supporting a Buy on Liquidia (LQDA) (Insider Monkey)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
Sep-01-25 01:04AM	BTIG Raises Price Target for Liquidia (LQDA), Keeps Buy Rating (Insider Monkey)
Aug-27-25 08:30AM	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-18-25 11:40PM	Court Victory and Fresh Funding Propel Growth at Liquidia Corporation (Insider Monkey) +6.82%
Aug-13-25 12:54PM	Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge (Insider Monkey)
03:08AM	Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YUTREPIA Launch and Financial Position (GuruFocus.com)
Aug-12-25 04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily) +13.68%
03:00PM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
06:30AM	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:22AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q2 2025 Result (GuruFocus.com)
Aug-05-25 08:30AM	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily) +5.75%
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jun-23-25 04:34PM	Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA (GlobeNewswire)
Jun-11-25 11:04AM	Insmed Stock Jumps 29% on Encouraging PAH Study Results (Zacks) -5.67%
Jun-10-25 04:07PM	Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia (Investor's Business Daily) -16.87%
Jun-02-25 06:30AM	Liquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD (GlobeNewswire) +13.07%
May-28-25 08:00AM	Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -9.13%
May-24-25 10:47AM	FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute (Insider Monkey)
May-23-25 02:28PM	U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (GlobeNewswire)
May-12-25 06:00AM	Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics (GlobeNewswire)
May-09-25 03:21AM	Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... (GuruFocus.com)
May-08-25 11:06AM	Buckley Capital's Views on Liquidia Corp. (LQDA) (Insider Monkey)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 06:35PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
11:16AM	Liquidia Q1 2025 Earnings Preview (Seeking Alpha)
10:15AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q1 2025 Result (GuruFocus.com)
May-06-25 08:00AM	Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
09:50AM	Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains? (Zacks)
May-02-25 05:28PM	District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia (GlobeNewswire) +13.23%
May-01-25 08:00AM	Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-30-25 09:30AM	Arquitos Capital's Largest Holdings For Q1 2025 (Seeking Alpha)
Apr-29-25 07:40AM	Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates (Zacks) -5.06%
05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-25-25 06:30AM	Arquitos Capital Management Q1 2025 Investor Letter (Seeking Alpha)
Apr-07-25 06:38AM	Liquidia: United Therapeutics Has The Last Laugh (Seeking Alpha)
Apr-01-25 10:33AM	UPDATE Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00AM	Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 09:30AM	Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA (treprostinil) Inhalation Powder (GlobeNewswire)
Mar-27-25 08:00AM	Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire)
Mar-21-25 06:23PM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q4 2024 Result (GuruFocus.com)
Mar-20-25 01:01AM	Q4 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-19-25 11:56AM	Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-25 08:00AM	Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million (GlobeNewswire)
Mar-12-25 08:00AM	Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors (GlobeNewswire)
Jan-22-25 09:12AM	Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jan-08-25 08:00AM	Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-24 07:11PM	Jim Cramer's Hidden Gem: Why Liquidia Corporation (LQDA) Is the Undervalued Stock You Need to Know (Insider Monkey)
Dec-12-24 10:00AM	Heres Arquitos Capital Managements Updates on Liquidia (LQDA) (Insider Monkey)
09:55AM	Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect? (Zacks)
Nov-26-24 09:55AM	Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-14-24 02:09AM	Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ... (GuruFocus.com)
Nov-13-24 07:40AM	Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 08:00AM	Liquidia to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyle Dana	Chief Accounting Officer	Jan 26 '26	Sale	41.65	1,580	65,807	178,848	Jan 28 04:30 PM
Adair Jason	Chief Business Officer	Jan 26 '26	Sale	41.65	688	28,655	211,169	Jan 28 04:30 PM
Krepp Sarah	Chief Human Resource Officer	Jan 12 '26	Sale	37.43	13,165	492,766	140,769	Jan 13 04:36 PM
Moomaw Scott	Chief Commercial Officer	Jan 12 '26	Sale	37.43	20,533	768,550	154,514	Jan 13 04:36 PM
Kaseta Michael	CFO and COO	Jan 12 '26	Sale	37.43	36,932	1,382,365	350,919	Jan 13 04:34 PM
Adair Jason	Chief Business Officer	Jan 12 '26	Sale	37.43	13,548	507,102	184,174	Jan 13 04:34 PM
Schundler Russell	General Counsel	Jan 12 '26	Sale	37.43	27,289	1,021,427	579,394	Jan 13 04:33 PM
JEFFS ROGER	Chief Executive Officer	Jan 12 '26	Sale	37.43	66,610	2,493,212	1,037,528	Jan 13 04:33 PM
Boyle Dana	Chief Accounting Officer	Jan 12 '26	Sale	37.43	11,047	413,489	156,700	Jan 13 04:31 PM
Saggar Rajeev	Chief Medical Officer	Jan 12 '26	Sale	37.43	21,142	791,345	176,883	Jan 13 04:31 PM
Schundler Russell	General Counsel	Dec 01 '25	Sale	32.19	1,072	34,508	577,288	Dec 02 04:34 PM
Krepp Sarah	Chief Human Resource Officer	Dec 01 '25	Sale	32.19	221	7,114	141,218	Dec 02 04:33 PM
Kaseta Michael	CFO and COO	Dec 01 '25	Sale	32.19	1,166	37,534	353,823	Dec 02 04:32 PM
Boyle Dana	Chief Accounting Officer	Dec 01 '25	Sale	32.19	303	9,754	155,031	Dec 02 04:31 PM
Adair Jason	Chief Business Officer	Dec 01 '25	Sale	32.19	693	22,308	175,868	Dec 02 04:31 PM
Moomaw Scott	Chief Commercial Officer	Dec 01 '25	Sale	32.19	831	26,750	154,506	Dec 02 04:30 PM
Adair Jason	Chief Business Officer	Nov 18 '25	Option Exercise	5.89	35,656	210,014	210,654	Nov 20 04:30 PM
Adair Jason	Chief Business Officer	Nov 18 '25	Sale	30.03	35,656	1,070,710	174,998	Nov 20 04:30 PM
JASON ADAIR	Officer	Nov 18 '25	Proposed Sale	28.40	35,656	1,012,630		Nov 18 04:23 PM
Boyle Dana	Chief Accounting Officer	Nov 07 '25	Sale	25.09	29,004	727,674	155,334	Nov 12 04:30 PM
Saggar Rajeev	Chief Medical Officer	Nov 05 '25	Sale	27.00	71,381	1,927,287	176,549	Nov 07 04:30 PM
Dana Boyle	Officer	Nov 07 '25	Proposed Sale	25.09	29,004	727,581		Nov 07 04:07 PM
Rajeev Saggar	Officer	Nov 05 '25	Proposed Sale	27.00	71,381	1,927,287		Nov 05 04:03 PM
Adair Jason	Chief Business Officer	Oct 27 '25	Sale	22.93	692	15,868	174,998	Oct 29 04:30 PM
Boyle Dana	Chief Accounting Officer	Oct 27 '25	Sale	22.93	1,073	24,604	184,338	Oct 29 04:30 PM
Schundler Russell	General Counsel	Oct 13 '25	Sale	23.41	7,839	183,511	576,017	Oct 15 04:36 PM
Kaseta Michael	CFO and COO	Oct 13 '25	Sale	23.41	11,630	272,258	352,646	Oct 15 04:34 PM
Moomaw Scott	Chief Commercial Officer	Oct 13 '25	Sale	23.41	4,900	114,709	153,462	Oct 15 04:34 PM
Saggar Rajeev	Chief Medical Officer	Oct 13 '25	Sale	23.41	5,327	124,705	247,930	Oct 15 04:33 PM
Boyle Dana	Chief Accounting Officer	Oct 13 '25	Sale	23.41	1,238	28,982	185,411	Oct 15 04:32 PM
JEFFS ROGER	Chief Executive Officer	Oct 13 '25	Sale	23.41	20,261	474,310	1,032,973	Oct 15 04:31 PM
Adair Jason	Chief Business Officer	Oct 13 '25	Sale	23.41	3,670	85,915	175,690	Oct 15 04:31 PM
Krepp Sarah	Chief Human Resource Officer	Oct 13 '25	Sale	23.41	1,691	39,586	141,439	Oct 15 04:30 PM
SINGH RAMAN	Director	Sep 15 '25	Option Exercise	2.55	45,524	115,865	76,779	Sep 17 04:30 PM
SINGH RAMAN	Director	Sep 15 '25	Sale	25.81	45,524	1,174,974	31,255	Sep 17 04:30 PM
RAMANDEEP SINGH	Director	Sep 15 '25	Proposed Sale	25.81	45,524	1,175,043		Sep 15 04:02 PM
SINGH RAMAN	Director	Sep 03 '25	Sale	29.42	7,500	220,650	31,255	Sep 05 04:30 PM
Singh Raman	Director	Sep 03 '25	Proposed Sale	29.42	7,500	220,650		Sep 03 04:34 PM
Moomaw Scott	Chief Commercial Officer	Sep 02 '25	Sale	28.63	70,692	2,023,671	155,254	Sep 03 04:33 PM
Schundler Russell	General Counsel	Sep 02 '25	Sale	29.05	1,063	30,880	580,098	Sep 03 04:33 PM
Krepp Sarah	Chief Human Resource Officer	Aug 29 '25	Sale	29.05	209	6,071	143,130	Sep 03 04:32 PM
Kaseta Michael	CFO and COO	Sep 02 '25	Sale	29.05	1,148	33,349	358,448	Sep 03 04:31 PM
Boyle Dana	Chief Accounting Officer	Aug 29 '25	Sale	29.05	296	8,599	186,649	Sep 03 04:30 PM
Manning Paul B	Director	Sep 02 '25	Sale	28.78	328,268	9,446,332	430,828	Sep 02 07:46 PM
Manning Paul B	Director	Aug 29 '25	Sale	27.62	188,232	5,198,968	759,096	Sep 02 07:46 PM
Manning Paul B	Director	Aug 28 '25	Sale	27.94	154,337	4,312,176	947,328	Sep 02 07:46 PM
Adair Jason	Chief Business Officer	Aug 28 '25	Sale	27.86	26,057	725,854	171,029	Sep 02 05:03 PM
Adair Jason	Chief Business Officer	Sep 02 '25	Sale	29.05	451	13,102	172,980	Sep 02 05:03 PM
Saggar Rajeev	Chief Medical Officer	Aug 28 '25	Sale	27.85	20,000	557,072	249,727	Sep 02 05:02 PM
SCOTT MOOMAW	Officer	Sep 02 '25	Proposed Sale	27.68	70,000	1,937,600		Sep 02 04:31 PM
Manning Paul B	Director	Aug 29 '25	Proposed Sale	27.60	947,328	26,146,253		Aug 29 04:18 PM
RAJEEV SAGGAR	Officer	Aug 28 '25	Proposed Sale	28.00	20,000	560,000		Aug 28 04:23 PM
JASON ADAIR	Officer	Aug 28 '25	Proposed Sale	28.00	26,057	729,596		Aug 28 04:19 PM
Manning Paul B	Director	Aug 28 '25	Proposed Sale	27.94	154,337	4,312,469		Aug 28 04:11 PM
Horobin Joanna	Director	Aug 19 '25	Sale	27.17	5,000	135,850	33,755	Aug 21 04:30 PM
Horobin Joanna	Director	Aug 19 '25	Proposed Sale	27.17	5,000	135,850		Aug 19 07:28 PM
Kaseta Michael	CFO and COO	Aug 15 '25	Sale	26.18	20,000	523,674	356,412	Aug 19 04:30 PM
Kaseta Michael	CFO and COO	Aug 05 '25	Sale	20.00	30,000	600,132	376,412	Aug 07 04:30 PM
MICHAEL KASETA	Officer	Aug 05 '25	Proposed Sale	19.48	50,000	974,000		Aug 05 05:02 PM
Adair Jason	Chief Business Officer	Jul 28 '25	Sale	19.54	454	8,871	193,180	Jul 30 04:31 PM
Boyle Dana	Chief Accounting Officer	Jul 28 '25	Sale	19.54	1,063	20,771	186,105	Jul 30 04:30 PM
Saggar Rajeev	Chief Medical Officer	Jul 21 '25	Sale	14.54	2,526	36,728	268,887	Jul 23 04:30 PM
Schundler Russell	General Counsel	Jul 14 '25	Sale	14.28	7,836	111,898	577,977	Jul 15 04:36 PM
Saggar Rajeev	Chief Medical Officer	Jul 14 '25	Sale	14.28	5,327	76,070	271,413	Jul 15 04:36 PM
Moomaw Scott	Chief Commercial Officer	Jul 14 '25	Sale	14.28	4,797	68,501	223,231	Jul 15 04:35 PM
Krepp Sarah	Chief Human Resource Officer	Jul 14 '25	Sale	14.28	2,673	38,170	142,499	Jul 15 04:35 PM
Kaseta Michael	CFO and COO	Jul 14 '25	Sale	14.28	11,580	165,362	406,412	Jul 15 04:34 PM
JEFFS ROGER	Chief Executive Officer	Jul 14 '25	Sale	14.28	20,252	289,199	1,038,560	Jul 15 04:33 PM
JEFFS ROGER	Chief Executive Officer	Jul 14 '25	Sale	14.28	20,252	289,199	1,038,560	Jul 15 04:33 PM
Boyle Dana	Chief Accounting Officer	Jul 14 '25	Sale	14.28	1,193	17,036	187,168	Jul 15 04:30 PM
Adair Jason	Chief Business Officer	Jul 14 '25	Sale	14.28	2,576	36,785	193,634	Jul 15 04:30 PM
Schundler Russell	General Counsel	Jun 04 '25	Sale	16.97	8,460	143,566	582,054	Jun 05 04:20 PM
Moomaw Scott	Chief Commercial Officer	Jun 04 '25	Sale	16.97	6,656	112,952	224,921	Jun 05 04:20 PM
Saggar Rajeev	Chief Medical Officer	Jun 04 '25	Sale	16.97	7,597	128,921	273,209	Jun 05 04:19 PM
JEFFS ROGER	Chief Executive Officer	Jun 04 '25	Sale	16.97	30,610	519,452	1,044,979	Jun 05 04:18 PM
Kaseta Michael	CFO and COO	Jun 04 '25	Sale	16.97	14,777	250,766	412,164	Jun 05 04:18 PM
Adair Jason	Chief Business Officer	Jun 04 '25	Sale	16.97	3,597	61,041	193,735	Jun 05 04:15 PM
Schundler Russell	General Counsel	Jun 02 '25	Sale	16.74	923	15,451	571,722	Jun 03 04:49 PM
Moomaw Scott	Chief Commercial Officer	Jun 02 '25	Sale	16.74	581	9,726	216,038	Jun 03 04:47 PM
Kaseta Michael	CFO and COO	Jun 02 '25	Sale	16.74	859	14,380	397,800	Jun 03 04:45 PM
Adair Jason	Chief Business Officer	Jun 02 '25	Sale	16.74	451	7,550	184,961	Jun 03 04:44 PM
Adair Jason	Chief Business Officer	Apr 28 '25	Sale	14.24	455	6,479	183,849	Apr 30 04:15 PM
Saggar Rajeev	Chief Medical Officer	Apr 21 '25	Sale	13.67	2,450	33,492	263,152	Apr 23 04:15 PM
Schundler Russell	General Counsel	Apr 14 '25	Sale	13.57	5,964	80,931	570,301	Apr 16 05:06 PM
JEFFS ROGER	Chief Executive Officer	Apr 14 '25	Sale	13.57	14,130	191,744	1,006,420	Apr 16 05:05 PM
Moomaw Scott	Chief Commercial Officer	Apr 15 '25	Sale	13.57	3,406	46,219	214,744	Apr 16 05:04 PM
Kaseta Michael	CFO and COO	Apr 14 '25	Sale	13.57	8,283	112,400	396,315	Apr 16 05:03 PM
Saggar Rajeev	Chief Medical Officer	Apr 14 '25	Sale	13.57	3,714	50,399	265,602	Apr 16 05:02 PM
Adair Jason	Chief Business Officer	Apr 14 '25	Sale	13.57	1,856	25,186	184,304	Apr 15 09:12 PM
Schundler Russell	General Counsel	Mar 03 '25	Sale	15.45	930	14,368	576,265	Mar 04 04:32 PM
Moomaw Scott	Chief Commercial Officer	Mar 03 '25	Sale	15.45	592	9,146	218,150	Mar 04 04:31 PM
Kaseta Michael	CFO and COO	Mar 03 '25	Sale	15.45	874	13,503	404,598	Mar 04 04:31 PM
Adair Jason	Chief Business Officer	Mar 03 '25	Sale	15.45	451	6,968	182,254	Mar 04 04:30 PM

TSHA

Taysha Gene Therapies Inc

CADL

Candel Therapeutics Inc

VRCA

Verrica Pharmaceuticals Inc

LQDA

Liquidia Corp

Upgrade your FINVIZ experience